Thrombocytopenia – Market Insight, Epidemiology and Market Forecast – 2027

Albany, Feb 13, 2019 (Issuewire.com) – Thrombocytopenia – Market Insight, Epidemiology and Market Forecast – 2027

The total prevalent cases of Thrombocytopenia were found out to be 1,607,983 in 2016.

More on StockNewDesk:

(Albany, US) DelveInsight launched a new report on Thrombocytopenia – Market Insight, Epidemiology and Market Forecast – 2027

Key topics covered
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Thrombocytopenia market.
Organize sales and marketing efforts by identifying the best opportunities for Thrombocytopenia market.
To understand the future market competition in the Thrombocytopenia market
The incidence of immune thrombocytopenia among adults in the USA is estimated to be 3.3 per 100,000 adults/year and the prevalence rate is 9.5 cases per 100,000. The annual prevalence is estimated at 5.3 per 100,000 among children.

Request for sample pages

Thrombocytopenia is one of the most common hematologic disorders, which is the leading cause of morbidity worldwide. The therapeutic market is mainly driven by the adulthood and childhood patient pools with an increase in prevalent cases. Market analysis study carried out for the period of 2016-2027 demonstrates that the Market size of Thrombocytopenia was about USD 1,183 million in 2016 in 7MM.

More on StockNewDesk:

Companies Covered:
1. Dova Pharmaceuticals
2. Rigel Pharmaceuticals
3. Bristol-Myers Squibb
4. UCB Biopharma
5. Biotest
6. Principia Biopharma
And many others

Table of contents

1. Key Insights
2. Thrombocytopenia Market Overview at a Glance
3. Disease Background and Overview: Thrombocytopenia
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Prevalent Population of Thrombocytopenia
4.4. Country Wise-Epidemiology of Thrombocytopenia
4.4.1. United States
4.4.2. Germany
4.4.3. France
4.4.4. Italy
4.4.5. Spain
4.4.6. United Kingdom
4.4.7. Japan
5. UNMET NEEDS
6. MARKETED PRODUCTS
6.1. OCTAGAM: OCTAPHARMA USA
6.2. NPLATE(AMG-531): AMGEN
6.3. MULPLETA (LUSUTROMBOPAG): SHIONOGI
6.4. PRIVIGEN: CSL BEHRING
6.5. RHOPHYLAC: CSL BEHRING
7. EMERGING THERAPIES
8. FILED & PHASE III DRUGS
8.1. Avatrombopag: Dova Pharmaceuticals
8.2. Fostamatinib: Rigel Pharmaceuticals
8.3. Caplacizumab: Ablynx
8.3.1.Drug Description
8.4. BT-595: Biotest
8.5. SHP655: Shire
9. PHASE II DRUGS
10. THROMBOCYTOPENIA: MARKET ANALYSIS
11. THROMBOCYTOPENIA: TOTAL MARKET SIZE IN 7MM
13. MARKET DRIVERS
14. MARKET BARRIERS
15. APPENDIX
15.1. Report Methodology
16. DELVEINSIGHT CAPABILITIES
17. DISCLAIMER
5.3. Japan
6. Treatments & Medical Practices
7. Marketed Product
7.1. Palynziq: BioMarin Pharmaceutical
7.2. Kuvan: BioMarin Pharmaceutical
8. Emerging Therapies
8.1. Key Cross Competition
8.2. SYNB-1618: Synlogic
8.3. CNSA-001: Censa Pharmaceuticals
9. Phenylketonuria (PKU) : Market Size
10. 7MM: Country-Wise Market Analysis
11. Market Drivers
12. Market Barriers
13. Report Methodology
14. DelveInsight Capabilities
15. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
[email protected]
+919650213330
SOURCE DelveInsight

Media Contact

Delveinsight Business Reserarch LLP

[email protected]

9193216187

304 S. Jones Blvd #2432, Las Vegas NV 89107

https://www.delveinsight.com/

Source :DelveInsight

This article was originally published by IssueWire. Read the original article here.

Latest on StockNewDesk:

Login

Lost your password?